▶ 調査レポート

肝臓がん治療薬の世界市場:治療法別(肝細胞がん、胆管細胞がん、肝芽腫、標的療法)、エンドユーザー別(小児、大人、その他)、地域別分析

• 英文タイトル:Global Liver Cancer Therapeutics Market - Segmented by Therapy Area, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。肝臓がん治療薬の世界市場:治療法別(肝細胞がん、胆管細胞がん、肝芽腫、標的療法)、エンドユーザー別(小児、大人、その他)、地域別分析 / Global Liver Cancer Therapeutics Market - Segmented by Therapy Area, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08315資料のイメージです。• レポートコード:B-MOR-08315
• 出版社/出版日:Mordor Intelligence / 2018年5月1日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥454,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥481,500 (USD4,500)▷ お問い合わせ
  Corporate User¥936,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、肝臓がん治療薬の世界市場について調べ、肝臓がん治療薬の世界規模、市場動向、市場環境、治療法別(肝細胞がん、胆管細胞がん、肝芽腫、標的療法)分析、エンドユーザー別(小児、大人、その他)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・肝臓がん治療薬の世界市場インサイト
・肝臓がん治療薬の世界市場環境
・肝臓がん治療薬の世界市場動向
・肝臓がん治療薬の世界市場規模
・肝臓がん治療薬の世界市場規模:治療法別(肝細胞がん、胆管細胞がん、肝芽腫、標的療法)
・肝臓がん治療薬の世界市場規模:エンドユーザー別(小児、大人、その他)
・肝臓がん治療薬の世界市場:地域別市場規模・分析
・肝臓がん治療薬の北米市場規模・予測
・肝臓がん治療薬のアメリカ市場規模・予測
・肝臓がん治療薬のヨーロッパ市場規模・予測
・肝臓がん治療薬のアジア市場規模・予測
・肝臓がん治療薬の日本市場規模・予測
・肝臓がん治療薬の中国市場規模・予測
・肝臓がん治療薬のインド市場規模・予測
・肝臓がん治療薬の韓国市場規模・予測
・関連企業情報・競争状況

The global liver cancer therapeutics market is expected to register a CAGR of around 8% during the forecast period (2018 – 2023). North America dominates the market due to the growing demand for cancer therapeutics.

Rising Incidence of Cancer

In 2017, according to the American Cancer Society, there would be 29,000 cases of cancer death in US. Liver cancer incidence has been rising in the US since the mid-1970s, and it is expected to continue to grow through till 2030. Change in the current lifestyle of individuals has led to the exposure of a large amount of population to the risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type 2 diabetes, metabolic disorders & excess body weight, alcohol consumption, and tobacco smoking. It has also been shown that liver cancer risk increases substantially with the increase in one’s body mass index (BMI). More than half of the adult population in the US is overweight. Along with this high demand for therapeutic drugs for liver cancer, this creates great opportunities for manufacturers to produce more drugs and create a competitive landscape.

Stringent Regulatory Policies for Therapeutics

In the expanding market for therapeutics, there are stringent regulatory policies in place to ensure the safety of such drugs. These policies are well studied. However, while rigorous regulatory procedures guarantee the quality of the product entering the market, they also delay the entry of a drug or device into the market which could be beneficial to patients suffering from a disease. Pre-market approval is an FDA process of scientific and regulatory review to evaluate the safety and effectiveness of drugs. There have been procedures by the FDA to heighten the post-market surveillance. The FDA review process takes twice the amount of time as the European regulatory commissions review bodies. Hence, citizens from countries where the review process is shorter benefit more than countries with longer review processes and stringent regulations. The presence of stringent regulations is dampening the innovation in the market and hindering the growth of this market. Strict regulatory policies have resulted in a reduction of investment by medical device manufacturers and drug companies in R&D of new products.

North America Dominates the Market

North America dominates the global liver cancer therapeutics market, owing to high incidence of liver cancer, technological advancement in therapeutics, and growing popularity of non-invasive radiation therapies in the region, leading to growing adoption of liver cancer therapeutics. Asia-Pacific is expected to grow during the forecast period owing to factors such as high prevalence of cancer, less stringent regulatory scenario, and presence of huge population base.

Key Developments in the Market

• September 2017 – Food and Drug Administration (FDA) granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®)for some patients with advanced liver cancer

Major Players: ALNYLAM PHARMACEUTICALS INC., ONYX PHARMACEUTICALS INC., F. HOFFMANN-LA ROCHE LTD., PFIZER INC., ARQULE INC., JENNEREX BIOTHERAPEUTICS INC., CELSION CORP., BAYER SCHERING PHARMA AG, 4SC AG, BRISTOL-MYERS SQUIBB COMPANY are amongst others.

Reasons to Purchase this Report

• Current and future global liver cancer therapeutics market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• Identifying the segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Incidence of Cancer
6.1.2 High unmet medical needs
6.1.3 Others
6.2 Market Restraints
6.2.1 Adverse effects of drugs
6.2.2 Poor patient adherence
6.2.3 Stringent regulatory Policies for Therapeutics
6.2.4 Others
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Therapeutics
7.1.1 Hepatocellular Carcinoma
7.1.2 Cholangio Carcinoma
7.1.3 Hepatoblastoma
7.1.4 Targeted Therapy
7.2 By End Users
7.2.1 Pediatrics
7.2.2 Adults
7.2.3 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest Of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Alnylam Pharmaceuticals Inc.
9.2 Onyx Pharmaceuticals Inc.
9.3 F. Hoffmann-La Roche Ltd.
9.4 Pfizer Inc.
9.5 ArQule Inc.
9.6 Jennerex Biotherapeutics Inc.
9.7 Celsion Corp.
9.8 Bayer Schering Pharma AG
9.9 4SC AG
9.10 Bristol-Myers Squibb Company
9.11 List Not Exhaustive
10. Future of the Market